Trials / Completed
CompletedNCT00056173
Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma
A Phase I/II Study of GTI-2040 and Capecitabine Combination Therapy in Patients With Advanced or Metastatic Renal Cell Carcinoma (mRCC)
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 43 (estimated)
- Sponsor
- Aptose Biosciences Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This phase II, 43 patient trial, will evaluate the efficacy of GTI-2040, an antisense oligonucleotide complementary to the R2 component of ribonucleotide reductase (RNR) mRNA, in combination with capecitabine, in the setting of advanced/metastatic renal cell carcinoma. Preclinical studies have shown synergy between GTI-2040 and capecitabine against renal cell carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GTI-2040 |
Timeline
- Start date
- 2002-03-01
- Primary completion
- 2004-12-01
- First posted
- 2003-03-10
- Last updated
- 2008-01-07
Locations
10 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00056173. Inclusion in this directory is not an endorsement.